Advanced Computing in the Age of AI | Saturday, December 3, 2022

Rainbow Coral to Enter 3D Bioprinting Market 

Thanks to new technology innovations pioneered by its partners at Nano3D Biosciences (n3D), Rainbow Coral Corp. is planning a major push into the skyrocketing 3D bioprinting market in 2014.

MIRAMAR BEACH, Fla., Jan. 16 -- Thanks to new technology innovations pioneered by its partners at Nano3D Biosciences (n3D), Rainbow Coral Corp. is planning a major push into the skyrocketing 3D bioprinting market in 2014.

Rising global demand in the medical industry for new and effective technologies has spurred tremendous interest in applying 3D printing methods to healthcare applications. The next wave of breakthroughs is now occurring in the field of bioprinting, which involves the printing of cell-loaded replicas of human tissues for the purposes of drug testing and regenerative medicine.

With the applications of such cutting-edge technology limited only by the imagination, industry analysts Transparency Market Research predicted last year that the medical 3D printing market will enjoy a compound annual growth rate of 15.4 percent over the next six years, expanding from a value of $345 million in 2012 to nearly a billion dollars in 2019.

RBCC is working closely with n3D to capitalize on this extraordinary growth. The companies are currently engaged in developing and marketing the BiO Assay: the first commercially available 3D bioprinting system designed for high throughput and high-content drug screening. The automated toxicity assay uses biocompatible magnetic nanoparticles to print cells into 3D structures much faster and more affordably than competing bioprinting tech made by competitors in the marketplace.

The BiO Assay represents a revolution in pharmaceutical research, offering better and faster results than have previously been possible.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

-----

Source: Rainbow Biosciences

Add a Comment

EnterpriseAI